# Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin & Gemcitabine for Urothelial Cancer

> **NCT00237575** · PHASE3 · TERMINATED · sponsor: **University of Kentucky** · enrollment: 100 (—)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** gemcitabine
- **DRUG:** cisplatin
- **DRUG:** sargramostim
- **DRUG:** filgrastim

## Key facts

- **NCT ID:** NCT00237575
- **Lead sponsor:** University of Kentucky
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-11
- **Primary completion:** 2006-03
- **Final completion:** 2006-03
- **Target enrollment:** 100 (—)
- **Last updated:** 2012-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00237575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00237575, "Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin & Gemcitabine for Urothelial Cancer". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00237575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*